Clinical Trial Update: Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerability study of NNC 0070-0002-0349 in overweight/obese volunteers has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NNC 0070-0002-0349

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 1 | Status: WITHDRAWN